Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer

NCT02506114 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

15

Enrollment

OTHER

Sponsor class

Stopped Low Accrual

Conditions

Prostatic Neoplasms

Interventions

BIOLOGICAL: PROSTVAC V/F
DRUG: Ipilimumab

Sponsor

Lawrence Fong

Collaborators

[object Object]